MK-1406 for Healthy Subjects
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines how a new treatment, MK-1406, behaves in the bodies of healthy individuals. Researchers aim to compare the effects and safety of MK-1406 when administered as either two or three injections, ensuring the treatment is safe and well-tolerated. This trial suits individuals in good health with a body mass index (BMI) between 18.0 and 32.0 kg/m². As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators.
Is there any evidence suggesting that MK-1406 is likely to be safe for humans?
Research has shown that MK-1406 is still under investigation for safety and effectiveness. Specific safety information from past studies is not yet available. This trial is in its first phase, indicating that MK-1406 is just beginning to be tested in people. Early-phase trials primarily focus on ensuring the treatment's safety. So far, MK-1406 has not been linked to any major health problems in people, or it would not have progressed to this testing stage.
Prospective participants should know that early trials often involve close monitoring to detect any side effects. These side effects could range from mild, such as headaches or nausea, to more serious. The goal is to assess how well people tolerate MK-1406 and to ensure its safety.12345Why are researchers excited about this trial's treatments?
MK-1406 is unique because it offers a new delivery method through subcutaneous injections, which can be administered in fewer doses compared to standard treatments. While most existing therapies for similar conditions may require multiple doses over an extended period, MK-1406 aims to simplify this with either a two or three-injection regimen on the first day. This streamlined approach could potentially enhance patient compliance and convenience. Researchers are excited about the possibility that MK-1406 might deliver effective results more swiftly and efficiently than current options.
What evidence suggests that MK-1406 might be an effective treatment for healthy subjects?
Research on MK-1406 remains in the early stages, so limited information exists on its efficacy. This trial will compare two dosing regimens: one group will receive 3 subcutaneous injections of MK-1406 on Day 1, while another group will receive 2 injections on the same day. The trial primarily aims to understand the drug's behavior in the body and assess its tolerability. Detailed information on MK-1406's mechanism is not yet available, leaving its potential benefits unclear. As MK-1406 is still under investigation, participants should understand that the trial focuses on safety and tolerability rather than proven effectiveness for any condition.26789
Who Is on the Research Team?
Medical Director
Principal Investigator
Merck Sharp & Dohme LLC
Are You a Good Fit for This Trial?
This trial is for healthy adults with a body mass index (BMI) between 18.0 and 32.0 who do not have any significant health problems.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either 2 or 3 subcutaneous injections of MK-1406 on Day 1
Follow-up
Participants are monitored for safety and pharmacokinetics of MK-1406, including adverse events and injection-site reactions
What Are the Treatments Tested in This Trial?
Interventions
- MK-1406
Trial Overview
Researchers are studying how the new drug MK-1406 behaves in the body when given as either two or three injections to healthy volunteers, and checking if it is safe and well-tolerated.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Participants receive 3 subcutaneous (SQ) injections of MK-1406 on Day 1.
Participants receive 2 SQ injections of MK-1406 on Day 1.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Merck Sharp & Dohme LLC
Lead Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University
Citations
1.
reports.merckgroup.com
reports.merckgroup.com/en/annualreport/2020/management-report/fundamental-information-about-the-group/research-and-development/healthcare.htmlHealthcare* - Merck Annual Report 2020
Early onset of action: Efficacy results from the Phase IV MAGNIFY-MS study, demonstrating an early onset of action from end of month one through ...
2.
fiercepharma.com
fiercepharma.com/pharma/merck-keytruda-hits-overall-survival-goal-early-lung-cancer-fda-decision-nearsMerck's Keytruda hits overall survival goal in early lung ...
Using Keytruda both before and after surgery significantly extended the lives of patients with stage 2 to 3b NSCLC in a phase 3 trial, Merck ...
3.
mmm-online.com
mmm-online.com/home/channel/data-analytics/a-tale-of-two-lung-cancer-immunotherapies-mercks-keytruda-takes-the-reins/A tale of two lung cancer immunotherapies: Merck's ...
Keytruda plus chemotherapy decreased the risk of death by 51% for newly-diagnosed patients with the advanced, non-squamous type of non-small ...
Merck to Present Extensive New Research Demonstrating ...
Efficacy and safety data from a Phase 2 study evaluating MK-2870/SKB264, Health-related quality of life (HRQoL) and pain outcomes for patients ...
5.
endpoints.news
endpoints.news/merck-increases-grip-on-its-lead-in-lung-cancer-winning-approval-for-keytrudachemo-combo-as-first-line-therapy/Merck increases grip on its lead in lung cancer, winning ...
Merck has won its bid to advance its leadership in treating the crucial non-small cell lung cancer market, gaining an FDA approval to start ...
Merck's Innovative Oncology Pipeline of DNA Damage ...
M9140 has shown high bystander activity, as exatecan released in the target tumor cells can kill these cells and also permeate the cell ...
Merck To Present Data at 2022 ASCO Annual Meeting
serious adverse reactions (≥1%) were acute kidney injury, adrenal insu ciency, pneumonia, colitis, and diabetic ketoacidosis (1% each). ic ...
8.
finance.yahoo.com
finance.yahoo.com/healthcare/articles/merck-mrk-wins-fda-expansions-111003871.htmlMerck (MRK) Wins FDA Expansions, Posts HIV Data, And ...
Merck and Gilead reported positive Phase 3 data for a once weekly oral HIV treatment regimen. Separately, Merck discontinued a Phase 3 lung ...
9.
biospace.com
biospace.com/merck-s-keytruda-significantly-lowers-risk-of-death-in-lung-cancer-patientsMerck's Keytruda Delivers Reduced Risk of Death in ...
patients who received adjuvant treatment with Keytruda (pembrolizumab) saw a 24% reduced risk of disease recurrence or death compared to those ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.